Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China

BMC Cancer

Lin Shen¹  Yun Chen²  Hongyan Li²  Cike Peng²  Ning Wang²  Xiaoyan Lin³  Dong Ma⁴  Honghao Fang⁵  Lingjun Zhu⁶  Qi Li⁷  Xiaohong Cai⁸  Ruihua Xu⁹  Weijia Fang^1,10  Wei Wang^1,11  Yongzhan Nie^1,12  Qingchuan Zhao^1,12  Bo Zhu^1,13 

[1] Beijing Cancer Hospital;Eli Lilly and Company China Affiliate;Fujian Medical University Union Hospital;Guangdong General Hospital;IQVIA;Jiangsu Province Hospital;Shanghai General Hospital;Sichuan Cancer Hospital and Institute;Sun Yat-sen University Cancer Center;The First Hospital of Zhejiang Province;The First People’s Hospital of Foshan;Xijing Hospital, Fourth Military Medical University;Xinqiao Hospital, Third Military Medical University;

关键词: Treatment patterns;    Colorectal cancer;    Medical records;    Real-world evidence;    China;   

DOI  :  10.1186/s12885-020-6557-5

来源: DOAJ

【 摘 要 】

Abstract Background Colorectal cancer (CRC) is the third most prevalent cancer in China but few large-scale studies were conducted to understand CRC patients. The current study is aimed to gain a real-world perspectives of CRC patients in China. Methods Using electronic medical records of sampled patients between 2011 and 2016 from 12 hospitals in China, a retrospective cohort study was conducted to describe demographics and disease prognosis of CRC patients, and examine treatment sequences among metastatic CRC (mCRC) patients. Descriptive, comparative and survival analyses were conducted. Results Among mCRC patients (3878/8136, 48%), the fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and other oxaliplatin-based regimens were the most widely-used first-line treatment (42%). Fluorouracil, leucovorin, irinotecan (FOLFIRI) and other irinotecan-based regimens dominated the second-line (40%). There was no a dominated regimen for the third-line. The proportion of patients receiving chemotherapy with targeted biologics increased from less than 20% for the first- and second- lines to 34% for the third-line (p < 0.001). The most common sequence from first- to second-line was from FOLFOX and other oxaliplatin-based regimens to FOLFIRI and other irinotecan-based regimens (286/1200, 24%). Conclusions Our findings reflected a lack of consensus on the choice of third-line therapy and limited available options in China. It is evident o continue promoting early CRC diagnosis and to increase the accessibility of treatment options for mCRC patients. As the only nationwide large-scale study among CRC and mCRC patients before more biologics became available in China, our results can also be used as the baseline to assess treatment pattern changes before and after more third-line treatment were approved and covered into the National Health Insurance Plan in China between 2017 and 2018.

【 授权许可】

Unknown